Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Monopar Therapeutics Inc.
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
November 9, 2026
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
November 2, 2026
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
August 20, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 20, 2026
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
June 1, 2026
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026